Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx~  * Gross total resection completed or planned~    * No less than gross total resection~   * No disease requiring staging surgery~* Prior gross total resection completed with one or more of the following risk factors:~  * Histologically proven multiple lymph node metastases~ * At least 1 lymph node with extracapsular extension of tumor~ * Positive margin(s) of resection, including mucosal margins and/or soft tissue or deep margins of resection OR~* Gross total resection planned within 14 days of study enrollment with anticipated need for postoperative radiotherapy for one of the following:~  * Multiple clinically/radiologically evident lymph nodes of at least 1.5 cm~ * Single clinically/radiologically evident lymph node of at least 3 cm~ * Histologically proven lymph node metastases~* No T3, N0 glottic cancer~* No nasopharyngeal or paranasal sinus carcinoma~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 21 and over~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* White blood cell (WBC) at least 3,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) no greater than 1.5 times ULN~Renal:~* Creatinine no greater than 1.5 ULN~Cardiovascular:~* No unstable angina~* No myocardial infarction within the past 6 months unless successfully treated with coronary artery bypass graft or percutaneous transluminal coronary angioplasty~* No uncontrolled arrhythmia~* No second or third degree heart block or other clinically significant conduction system abnormality unless pacemaker is in place~Pulmonary:~* No severe chronic obstructive pulmonary disease requiring 3 or more hospitalizations within the past year~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No pre-existing grade 2 or greater peripheral neurotoxicity~* No other prior malignancy within the past 3 years except low-risk nonmelanomatous skin cancer; carcinoma in situ (e.g., breast, cervix, or bladder); or stage T1-2, low to moderate grade prostate cancer~* No significant wound infection~* No fistula~* No major wound dehiscence~* Nutritional status adequate~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Concurrent colony-stimulating factors for neutropenic fever during study chemoradiotherapy allowed~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy to head and neck~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery, chemotherapy and radiation therapy (Type: EXPERIMENTAL): Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete